The outlook of companies tied to the drug's past presents a complex investment picture . While the initial success generated substantial gains, generic competition have significantly eroded revenue. Investing in related pharmaceutical companies now requires a careful assessment of intellectual property safeguards, evolving healthcare shifts , and t